Gene and cell therapy group Oxford BioMedica plc (LSE: OXB) has entered into a collaboration to develop a novel gene therapy treatment for cystic fibrosis, the company revealed on Monday.
Oxford BioMedica will work with the UK Cystic Fibrosis Gene Therapy Consortium (GTC) and Imperial Innovations to develop a long-term therapy for patients with cystic fibrosis, focusing on a novel, replication deficient lentiviral vector, in an inhaled formulation, to selectively introduce a CFTR gene into the relevant target cell.
According to Oxford BioMedica, this approach has demonstrated high gene transfer efficiency and offers the possibility of repeated administration to maintain a therapeutic effect. In addition, the approach has the potential to address all of the more than 2,000 different, known gene mutations across patients equally well, and thus offer a disease-modifying treatment option for all patients.
Under the process development collaboration agreement, Oxford BioMedica will be responsible for process and analytical development, scale up of manufacture of the candidate and generation of material for toxicology studies. In the future, the parties also may establish a clinical supply agreement.
Additionally, the collaboration may include an evaluation of Oxford BioMedica's Transgene Repression in vector Production (TRiP) System, and the development of stable producer cell lines for large-scale production of the lentiviral vector.
Under a separate option and licence agreement with Boehringer Ingelheim, Oxford BioMedica has granted the German company an option to license the exclusive global rights over Oxford BioMedica's lentiviral vector technology to manufacture, register and commercialise this lentiviral vector-based gene therapy for the treatment of cystic fibrosis. Financial terms of the agreement were not disclosed.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera